
    
      This is a Phase 3, single-arm, open-label, multicenter clinical trial to evaluate both the
      efficacy and long-term safety of lomitapide in Japanese patients with HoFH receiving
      maximally-tolerated, stable lipid-lowering therapy. This study is comprised of a run-in
      period, a primary 26-week Efficacy Phase, and a 30-week Safety Phase.
    
  